Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
G Sheehan-Dare, S Khan, L Emmett
European Urology Focus, 2026
Elsevier
A key unanswered question in prostate-specific membrane-antigen (PSMA) targeted radioligand therapy is whether we have chosen therapy doses and regimens that are “safe” rather than “effective,” with phase 3 trials to date guided by conservative external beam derived dose constraints. However, is increasing administered dose or short interval fractionated dose safe, and does it even make a difference to patient outcomes? The goal of the OPTIMAL-PSMA trial is to determine the depth of response and safety of intense …
